

Purvalanol B

Catalog No: tcsc1714



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

212844-54-7

Formula:

$C_{20}H_{25}ClN_6O_3$

Pathway:

Cell Cycle/DNA Damage

Target:

CDK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 40 mg/mL (92.40 mM)

Alternative Names:

NG 95

Observed Molecular Weight:

432.9

Product Description


Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.

IC50 Value: 6 nM(cdc2/cyclin B); 6 nM(cdk2/cyclin A); 9 nM(cdk2/cyclin E); 6 nM(cdk5-p35)[1]

Target: cdc2/cyclin B; cdk2/cyclin E; cdk5-p35

in vitro: In vitro inhibitory activity against Cyclin-dependent kinase 1-cyclin B complex from starfish oocytes is 6 nM (IC50) [1]. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases [2].

in vivo:



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!